Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04942665 · ClinicalTrials.gov registry record · Phase 2
Low Dose ICG for Biliary Tract and Tumor Imaging
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT04942665 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 60 participants.
The verdict
NCT04942665, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG) allows for the intraoperative identification of liver anatomy. The investigators have new data that a much lower dose improves this visualization. Confirmation of this hypothesis would mean that ICG can be administered on the same day of surgery in order to augment real-time intraoperative visualization, thereby providing a safe, feasible, and cost-effective strategy for the surgical treatment of liver disease.
Interventions
- DRUG Indocyanine green
- DEVICE PINPOINT Endoscopic Fluorescence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2023-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04942665
The ClinicalTrials.gov registry entry for NCT04942665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indocyanine green is the first listed.
NCT04942665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04942665 about?
NCT04942665 is a clinical study titled "Low Dose ICG for Biliary Tract and Tumor Imaging". Near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG) allows for the intraoperative identification of liver anatomy. The investigators have new data that a much lower dose improves this visualization. Confirmation of this hypothesis would mean that ICG c...
What is the current status of trial NCT04942665?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-09-15. Estimated completion is 2023-04-01.
What interventions are being tested in trial NCT04942665?
The interventions under investigation include: Indocyanine green (DRUG), PINPOINT Endoscopic Fluorescence (DEVICE).
Who is sponsoring clinical trial NCT04942665?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.